Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions.
about
Mechanisms of disease reversal in focal and segmental glomerulosclerosisMechanisms underlying renoprotection during renin-angiotensin system blockade.High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathyMechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease.Increased capillary branching contributes to angiotensin type 1 receptor blocker (ARB)-induced regression of sclerosisRenal function can improve at any stage of chronic kidney disease.Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat.Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidneyMineralocorticoid Receptor Blocker Protects against Podocyte-Dependent GlomerulosclerosisThe molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic miceRole of remission clinics in the longitudinal treatment of CKD.Clinically Relevant Doses of Enalapril Mitigate Multiple Organ Radiation Injury.Proteinuria impairs podocyte regeneration by sequestering retinoic acid.New renal drug development to face chronic renal disease.Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study.Progression of glomerulonephritis.The role of renin angiotensin system inhibition in kidney repair.Metabolic responses of extracellular matrix in tissue repair.The targeted podocyteEffect of angiotensin converting enzyme inhibitor on collagen production by cultured mesangial cells.Dose-dependent effects of angiotensin converting enzyme (ACE) inhibitors on glomerular prostanoid production by normotensive ratsEffects of captopril on morphologic changes in kidney of spontaneously hypertensive rats with adriamycin nephropathy.Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells.
P2860
Q27010135-B2AF1333-896C-4117-9C9A-559EA172F664Q32032668-C9D6C06C-79A4-4447-B36B-5820BA002272Q33813308-C2CA5DFA-B0E2-4325-BFC3-4E5A5B7BB305Q34331403-37135215-0BEC-48F6-9DCE-33D92AF9BC41Q34761204-605DCB56-712B-4EFC-94A4-8AD82EA89D58Q34805601-58FDBCC8-FD6B-4130-B7C5-DBC4C46D028FQ35069799-4BF275F3-5EBA-41C1-92A4-EE86816F78E4Q35261898-722C1A44-E6E3-4A64-A1B5-9E71971687CBQ35608784-F140CB43-463B-4BFA-8D01-36F9D871D7BAQ35752878-95D6B7E3-83B3-4270-B15F-98A238E7F530Q35868694-47E2DAF6-503C-4FAE-BF6E-8673F72117CAQ36437448-DE788BC1-F507-49E8-80F0-2867B072CA27Q36677647-4876C940-A74C-4CA4-9CB1-6B38A376F564Q36781470-68466E89-8FEB-42AE-934C-BBD8E368EA2DQ37260185-C9EDF2FE-C8ED-4468-8B7A-CB9BA08F5C73Q38246640-E9A66923-5FD5-4531-9039-E5DBF641629CQ40333027-CBECA84F-B70D-4CE3-8042-77F125B36FDFQ41197802-E5AC94B8-B73E-4730-A9F5-DEFF9ADCB64DQ41206891-031EDDDA-A910-454B-A8A0-A24ABFD828CFQ41647752-AAF5E676-F9E0-4586-B164-E4C8E7D1E705Q41859454-77051280-6E9E-48FD-8497-9930FE3C9D50Q42431797-E7226A08-E1AA-4FB9-A57C-D2E5461D34CEQ42510414-C231982F-CDCF-4C5B-A6DC-4C07C5BE682FQ42542114-5A204DE7-BF96-48C7-8F75-BE7F3EA6B0E5Q44838071-475F1C11-7447-43DF-B5BE-8BAD56FA160BQ46821553-36273ACF-3B37-4F4C-AD37-9BE1F32708AC
P2860
Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@en
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@nl
type
label
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@en
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@nl
prefLabel
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@en
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@nl
P2093
P356
P1433
P1476
Cause of variable therapeutic ...... hibitor on glomerular lesions.
@en
P2093
P2888
P304
P356
10.1038/KI.1991.200
P407
P577
1991-08-01T00:00:00Z